Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the prese...

Full description

Bibliographic Details
Main Authors:	Park, Jin H., Liu, Yingting, Lemmon, Mark A., Radhakrishnan, Ravi
Format:	Online
Language:	English
Published:	Portland Press Ltd. 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507260/

Similar Items

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
by: Levinson, Nicholas M, et al.
Published: (2006)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
by: Nguyen, Kim-Son H, et al.
Published: (2012)

Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression
by: Suárez-Arroyo, Ivette J., et al.
Published: (2016)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
by: Pao, William, et al.
Published: (2005)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
by: Choi, Yun Jung, et al.
Published: (2013)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Huang, Lihua, et al.
Published: (2015)

Conformational changes in the catalytically inactive nucleotide-binding site of CFTR
by: Csanády, László, et al.
Published: (2013)

Predicting Inactive Conformations of Protein Kinases Using Active Structures: Conformational Selection of Type-II Inhibitors
by: Xu, Min, et al.
Published: (2011)

Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
by: Bahce, Idris, et al.
Published: (2016)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
by: Park, Ha Young, et al.
Published: (2016)

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain
by: GUILLAUDEAU, ANGÉLIQUE, et al.
Published: (2011)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
by: Costa, Daniel B, et al.
Published: (2007)

Conformational Differences between Active Angiotensins and Their Inactive Precursors
by: Solopova, O.N., et al.
Published: (2012)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Elloumi-Mseddi, Jihene, et al.
Published: (2013)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
by: Gonçalves, Ivone, et al.
Published: (2013)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, Lichun, et al.
Published: (2015)

Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib
by: Xie, Shengzhi, et al.
Published: (2015)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
by: Arakawa, Nobuhito, et al.
Published: (2013)

Computational Design of Binding Proteins to EGFR Domain II
by: Choi, Yoon Sup, et al.
Published: (2014)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
by: Wang, Xin, et al.
Published: (2014)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
by: Tabara, Keisuke, et al.
Published: (2012)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
by: He, Peng, et al.
Published: (2013)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
by: Vouri, M, et al.
Published: (2016)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang, Wenxian, et al.
Published: (2016)

Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
by: Huang, Chien-Chang, et al.
Published: (2016)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang, Jun, et al.
Published: (2016)

c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution
by: Badger, John, et al.
Published: (2016)

Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma
by: Tseng, Jeng-Sen, et al.
Published: (2014)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
by: Nakade, Junya, et al.
Published: (2014)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
by: Kim, Hye Sook, et al.
Published: (2013)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
by: Levinson, Nicholas M., et al.
Published: (2012)

Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells
by: Dransfield, I, et al.
Published: (2015)

Ca2+/Calmodulin and Apo-Calmodulin Both Bind to and Enhance the Tyrosine Kinase Activity of c-Src
by: Stateva, Silviya R., et al.
Published: (2015)

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
by: Lee, Victor H. F., et al.
Published: (2016)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
by: Slobbe, Paul, et al.
Published: (2015)

A Selective NMR Probe to Monitor the Conformational Transition from Inactive to Active Kinase
by: Xie, Qian, et al.
Published: (2014)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
by: Azuma, Koichi, et al.
Published: (2016)

Overcoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding
by: Novotny, Chris J., et al.
Published: (2016)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
by: Ji, Wonjun, et al.
Published: (2013)

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
by: Chang, Hyun, et al.
Published: (2016)